View Older Stories View More Recent Stories
-
Novo Nordisk (NVO) : Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
-
Novo Nordisk (NVO) call put ratio 1 call to 1 put as share price pulls back
-
Novo Nordisk (NVO) and Valo Health expand collaboration to discover and develop novel treatments for cardiometabolic diseases
-
UBS Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Buy
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
Bernstein SocGen Group Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Market Perform
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Novo Nordisk (NVO) PT Lowered to $105 at BMO Capital
-
Novo Nordisk (NVO) options active on 195K contracts amid sharp move lower
-
KeyBanc Weighs in on GLP-1 Injection Leaders Following Latest NVO Results
-
Bernstein SocGen Group Reiterates Underperform Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NVO) January 3 weekly 110 and June 115 calls active as share price down 17.8% after releasing Cagrisema data
-
Novo Nordisk (NVO) PT Lowered to $105 at BMO Capital
-
Novo Nordisk (NVO) call put ratio 1.7 calls to 1 put after releasing Cagrisema data
-
Viking Therapeutics (VKTX), Others Gain After Novo Nordisk (NVO) Data Falls Short of Expectations
-
Novo Nordisk (NVO) reports data from CagriSema REDEFINE 1 trial
-
Hims & Hers Health (HIMS) Quickly Falls 9% after FDA Says the Obesity Drug Shortage Ended
-
Novo Nordisk (NVO) Completes $16.5B Acquisition of Catalent
-
CFRA Starts Novo Nordisk (NVO) at Hold
-
Ozempic Study Found Small Number Of Patients With Vision Loss - Bloomberg
-
Bernstein: 'GLP-1s vs. the Weight of the World'
-
Buy this fast-growing European pharma stock, TD Cowen says
-
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO); Stock Named Best Idea 2025
-
Bernstein: 'Could the lion's share of China GLP-1 market go to domestic players?'
-
3 catalysts that could send this GLP-1 stock surging: BofA
-
Catalent (CTLT) and Novo Holdings (NVO) Receive European Commission Unconditional Approval for Pending Transaction
-
BMO Capital: Five Key BioPharma Catalysts Through Year-End '24
-
Lilly Products Show Strength Heading Into the Holiday
-
Amgen (AMGN) Falls 8% Following Obesity Data, Rivals Lilly (LLY), Novo Nordisk (NVO) Gain 4%
-
Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Eli Lilly & Co. (LLY) and Novo Nordisk (NVO) gain on Biden's GLP-1 proposal
-
Novo Nordisk (NVO) call put ratio 2.9 calls to 1 put into share price up before the bell
-
BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO)
-
Barclays Reiterates Overweight Rating on Novo Nordisk (NOVOB:DC) (NVO) into 'the most eagerly awaited clinical catalyst for our space of this year'
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Novo Nordisk added to Citi's Europe 1 list of top ideas
-
JPMorgan Reiterates Overweight Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK1,000 at Deutsche Bank
-
Novo Nordisk (NVO) Reports Q3 EPS of DKK6.12; offers outlook
-
Novo Nordisk (NVO) call put ratio 1.6 calls to 1 put as share price down 1%
-
Novo Nordisk (NVO) call put ratio 2.2 calls to 1 put into quarter results
-
Novo Nordisk (NVO) call put ratio 1.4 calls to 1 put into quarter results
-
Madrigal Pharma (MDGL) Falls 9.3% Following Data from Novo Nordisk (NVO)
-
Novo Nordisk (NVO) announces Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
-
Tiziana Life Sciences (TLSA) Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
-
Erste Group Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold, 'strong growth'
-
Obesity Drug Coverage Could Boost Spending By $35B Through 2034: CBO
-
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO)
-
UBS Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK1,075 at BofA Securities

